Pharmaceutical company Jubilant Life Sciences has reported 8.03 per cent increase in its consolidated net profit to Rs 79.36 crore for the quarter ended September 30 over the same period last fiscal. The company had achieved a net profit of Rs 73.46 crore for the quarter ended September 30, 2010, the company said in a statement.
Consolidated net sales of the company stood at Rs 1,048.08 crore for the quarter ended September 30 as against Rs 858.97 crore in the corresponding period previous fiscal.
International business from 75 countries contributed 70 per cent to net sales at Rs 730 crore. Sales from regulated markets of the US, Canada, Europe and Japan were at Rs 608 crore and amounted to 58 per cent of the net sales.
Commenting on the company's performance, Mr Shyam S. Bhartia, Chairman and Managing Director said, “Generics business led the growth in terms of revenue and profitability, leading to higher contribution from the segment. Services business witnessed a substantial turnaround with increase in margins and sales growth and is expected to continue the performance due to strong order book and higher capacity utilisation.”
“Our growth momentum should continue in the following quarters backed by the commissioning of new capacities lined up for the year; innovation-led new product launches and expansion in focused geographies in products business, with sustained higher margins in services business,” he added